We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Natalizumab

News List

Polpharma Biologics Announces Approval of Europe’s First and Only Biosimilar for Multiple Sclerosis - Tyruko® (Natalizumab) B3C newswire
November 06, 2023
Polpharma Biologics, today announced that the European Commission (EC) has approved Tyruko® (natalizumab) as the first and only biosimilar for relapsing forms of multiple sclerosis (MS) in Europe.
Polpharma Biologics Announces First-of-a-Kind Multiple Sclerosis Biosimilar Natalizumab Receives Positive CHMP Opinion PharmaSources
July 24, 2023
Polpharma biologics announces first-of-a-kind multiple sclerosis biosimilar natalizumab receives positive CHMP opinion.
Sandoz announces global deal to commercialize proposed biosimilar natalizumab, a key multiple sclerosis medicine worldpharmanews
September 06, 2019
Sandoz, a Novartis division and a global leader in biosimilars, announced that it has entered into a global commercialization agreement for a proposed natalizumab biosimilar.